A 15-item MMPI scale has been developed that relates to the reported frequency of panic-fear symptoms on the Asthma Symptom Checklist (ASC). High scale scores describe fearful, emotionally labile individuals who profess to be more sensitive than others and unable or disinclined to persist in the face of difficulty. The relationship between the MMPI panic-fear scale and the ASC panic-fear symptoms is highly replicable and related to a crucial aspect of chronicity in asthma. High scoring asthmatic patients were prescribed more intensive discharge steroid regimens upon completion of residential treatment. This relationship was not mediated by available objective pulmonary function measurements used to index medical condition. Development of the MMPI panic-fear scale should enable further investigation of personality and behavioral aspects related to the perceived severity and intractability of other medical conditions and disabilities.
INTRODUCTION
Chronic illness and disability affect millions, exact an enormous personal cost, and require a disproportionately large public expenditure for treatment and rehabilitation (1) . For some chronic patients, emotional factors may contribute to chronicity through incapacitation, overdependence on medications, and overutilization of medical services. Because these issues strike jointly at humanistic concerns and public policy, a fresh look at personality variables and related behaviors associated with medical overutili-zation and perpetuation of illness is needed.
One approach is to select as a point of departure personality characteristics already well studied in chronic diseases such as asthma. Asthma is characterized by the intermittent appearance of symptoms related to airway obstruction and by having a wide range of symptom severity. In view of the chronic, intermittent nature of asthma, it can be understood in terms of behavioral as well as medical exacerbating factors.
It has been suggested that psychological variables are more profitably understood in the maintenance than in the etiology of asthma, and that it is more useful to examine individual personality patterns than to look for universal constellations characteristic of all asthmatics (2) . In an effort to understand how the disease is experienced by patients and how that experience is translated into behavior affecting the course of the illness, Kinsman and his co-workers (3) developed the Asthma Symptom Checklist (ASC). The ASC measures five categories of subjective PANIC-FEAR IN ASTHMA symptoms reported to occur during asthma attacks: Panic-Fear, Irritability, Fatigue, Hyperventilation-Hypocapnia, and the target symptoms of Airway Obstruction. The frequency with which the symptoms of each category are reported varies widely among asthmatic patients and enables classification of patients according to their reported symptomatology.
Subsequent research (4-6) has found a significant relationship between the category of panic-fear and the intensity of the steroid drug regimen prescribed at discharge from residential treatment, months after administration of the ASC. Furthermore, panic-fear symptomatology has been found to be unrelated to objective medical condition indexed by several spirometric pulmonary function measures. It appears that this characteristic of asthmatics may be related to perceived severity in asthma in that high panic-fear profiles engender intensified treatment.
The ASC is not widely known and is appropriate for use only with asthmatics. In an effort to extend the applicability of its concepts to other chronic illnesses, Dirks (7) explored the relationship between panic-fear and standard scales of the Minnesota Multiphasic Personality Inventory (MMPI). Surprisingly, no individual MMPI scale or any combination of scales in a multiple regression adequately predicted panic-fear scores. The present study was designed to derive a new MMPI scale by identifying individual items related to panic-fear scores. This effort should enable broader conceptualization of the panic-fear dimension and permit its application to other chronically ill populations. Additionally, validation of the new scale is reported by a prospective study to predict panic-fear scores and perceived severity in asthma defined by the nature and intensity of prescribed medical regimens.
METHOD

Subjects
The subjects were 237 adult and adolescent inpatients, 89 male and 148 female, ranging in age from 14 to 72 years. They were administered both the Asthma Symptom Checklist (ASC) and the Minnesota Multiphasic Personality Inventory (MMPI) within 2 weeks after admission to the residential treatment program at National Jewish Hospital and Research Center (NJHRC). During treatment, spirometric pulmonary function measurements were obtained at 8:00 a.m. each day for all patients. These included Forced Expiratory Volumes in One Second (FEVi), Forced Vital Capacities (FVC), and Peak Flow (PF) measures (8) . Using the available measurements, the forced expiratory volumes during the first second (FEVi), expressed as a percentage of the forced vital capacity (FEVi /FVC%), can also be derived from these measures to index airway obstruction.
The patients were a representative sample from the hospitalized asthmatics at NJHRC, which has been described elsewhere (6) . Allergic (i.e., reaginic) factors, determined by skin testing and antigen inhalation challenge (9), were typically involved in 37% of the cases, infection in 86%, and both allergy and infection in 21%. Approximately 72% of these patients were prescribed maintenance steroids at the time of discharge from the hospital. Characteristic of hypersensitivity of the airways in asthma, all patients were hyperreactive to methacholine and /or histamine, i.e., increased airway obstruction developed in varying degrees upon inhalation of small, measured quantities of these substances (10) . The patients thus represented a heterogeneous group of severe, perennial asthmatics.
Procedure
Initial item selection was based on a group of 36 patients. Defined by ASC panic-fear scores (mean = 2.79, SD = 1.05) these patients were separated into three groups: low panic (ASC T-scores < 40, N = 10), moderate panic (40 « ASC T-score =s 60, N = 13), and high panic (ASC T-score > 60, N = 13). Sex and age were equated between groups. All MMPI items contributing to the three standard validity scales, to the 10 standard clinical scales, and to Barron's Ego Strength (Es) and Dependency (Dy) scales were tallied for patients within each group. By inspection, 38 MMPI items were selected that best differentiated the three groups. The patient sample was then increased to 71, age and sex again equated among groups, and the 38 items were tested by chi-square to identify those significantly differentiating groups. The items selected were then scored as a scale permitting empirically derived cut-points to be established that best predicted the panic-fear category for the 71 patients.
Subsequent analyses were performed to (1) validate the prediction of the MMPI panic-fear scale on a new group of patients and to (2) evaluate its ability to predict intensity of discharge steroid regimen. For all analyses, 0.05 was regarded as the probability level representing statistical significance.
RESULTS
Scale Derivation and Replication
Based on the total standardization group of 71 patients, 15 MMPI items were selected that significantly differentiated by chi-square test between low, moderate, and high panic-fear groups. These items are shown in Table 1 . In the table, the Pearson product moment correlations between each item and the ASC panic-fear category are also presented along with the MMPI standard scale membership.
For the original 71 patients, scale scores were calculated by a simple additive sum after reverse scoring of negatively correlated items. Empirically derived cutpoints revealed that a scale score of 2 or less best predicted the ASC low panic-fear group, 3 to 8 the moderate panic-fear group, and 9 or greater the high panic-fear group. Using these cut-points, the 15-item MMPI scale correctly assigned 65% of the patients to the appropriate ASC panic-fear groups [K 2 = 31.16, d/ = 4, P <0.001) as shown in Table 2a . These results are even more impressive when considered as a 2 x 2 breakdown into high panic-fear patients and others according to ASC panic-fear and the MMPI scale: 85% of the patients were assigned correctly ( To validate the MMPI panic-fear scale, a prospective study was conducted with 46 additional adult asthma patients, including three low ASC panic-fear patients, 30 moderates,and 13 highs. Using the previously established cut-points, the MMPI panic-fear scale correctly assigned 78% of the patients to the three ASC panic-fear groups (^2 = 29.77, df = 4, P <0.001) as shown in Table 2b . For this new group, the correct assignment in a 2-way breakdown to high panic-fear versus others was again 85% (K 2 = 16.83, df = 1,P <0.001). These results indicate that the MMPI scale consistently predicts the ASC panic-fear levels upon replication.
Scale Application: Relationship to Recommended Discharge Drug Regimens The intractability of asthma can be operationally defined in a number of ways. A principal objective of residential treatment is to select a drug regimen that best manages a patient's asthma. Steroids are among the most effective drugs often recommended at discharge following longitudinal observation of each patient. However, since steroids represent a category of medications that have particularly severe side effects, the physician's recommendation to use steroids at NJHRC follows an established philosophy: (1) If the patient's asthma can be controlled without steroids, none are recommended at discharge, (2) if the patient's asthma cannot be managed without steroids, steroids are recommended on an alternate-day basis to minimize side effects, (3] only if the patient is judged to have very severe, difficult to manage asthma will daily steroids be recommended. On this basis, the nature of the steroid regimen recommended at discharge (none, alternate day, daily] has been used in the past as one index of the intractability of asthma (4, 5) . More recently, the use of daily and alternate-day steroids has decreased during residential treatment due to the increased use of new investigational drugs to minimize steroid side effects. This necessitated an a priori revision of the drug categories to preserve the continuum of intensity while adhering to the advances in medical treatment. The discharge drug categories selected prior to any analyses were no steroids, alternate-day steroids, and augmented alternate and daily steroids. While the first two categories are self-explanatory, the final category includes principally alternate-day steroids augmented by one or more special drugs as well as a lesser percentage of actual daily steroid regimens. A more complete explanation of the medical philosophy underlying these drug categories, their composition, and special drugs included is presented elsewhere (6) .
For a group of 120 patients, the recommended steroid regimen at discharge (none alternate day, augmented alternate and daily) was determined by referral to the discharge summaries. The MMPI panicfear scale was related to the discharge steroid regimens using the established cut-points. The results, presented in Table  3 , indicate that patients scoring high on the MMPI panic-fear scale are more often assigned augmented alternate or daily steroid regimens and less often prescribed no steroids at discharge (K 2 = 17.11, d/ = 4, P <0.01). Moreover, the MMPI panicfear scale predicted steroid regimens at discharge even somewhat better than did the ASC panic-fear scores. Mean levels of pulmonary functioning for the 1-month period bracketing administration of the MMPI did not differ among groups of patients for any pulmonary function measurement.
DISCUSSION
Based on an original standardization group of 71 hospitalized asthmatics, a 15-item MMPI panic-fear scale has been developed. The scale differentiates asthmatics according to the frequency with which they report panic-fear symptoms to accompany asthma attacks. The scale has been demonstrated to be replicable and related to perceived severity of asthma as defined by intensity of recommended steroid regimens. Thus, it appears to have the predictive validity and replicability to be used clinically in individual cases.
Perhaps more importantly, the development of the scale contributes to a broader conceptualization of the panicfear dimension. In terms of item content, it appears to describe emotionally labile and 
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fearful individuals who regard themselves as being more sensitive than others and who acknowledge an inability or disinclination to persist in the face of difficulty. This picture would be consistent with individuals who are likely to be easily defeated by a variety of chronic illnesses or disabilities. We suspect that the complicating effect of panic-fear may not be limited to asthma, and that the development of this scale will permit exploration of its relevance to an understanding of chronicity in other medical problems. Efforts are now needed to relate the MMPI panic-fear scale to other indices of intractability, e.g., duration of hospitalization, response to medical treatment, and coping behaviors, and to determine its role in other chronic illnesses.
SUMMARY
Chronic illness is being recognized as a major social problem. Intractability attributable to personality characteristics may confuse the medical picture in such illness and contribute to a disproportionate utilization of medical services by a small segment of the population. This study reports the development of a personality assessment instrument for identification of intractable patient groups.
The Asthma Symptom Checklist (ASC) reported elsewhere (3-6) measures several categories of symptoms reported to occur during asthma attacks. One of those, panic-fear, has been shown to relate to the intensity of steroid drug regimens recommended at discharge from residential treatment, months after testing.
Since the ASC is limited to use with asthmatics, the present 15-item MMPI scale was developed to capture the panicfear concept in a measure applicable to other chronically ill populations. This MMPI scale classifies asthmatic patients according to their ASC Panic-Fear scores with considerable accuracy, predicts the intensity of discharge steroid regimens, and provides descriptive information about those who score high on panic-fear.
Early identification of patients whose illness is compounded by panic-fear should permit physicians to design more effective therapeutic plans involving adjunct therapies to minimize the influence of this coping style during treatment.
